423 related articles for article (PubMed ID: 25399680)
1. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
Cytometry B Clin Cytom; 2015 Mar; 88(2):101-9. PubMed ID: 25399680
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
Cytometry B Clin Cytom; 2014 Oct; ():. PubMed ID: 25349085
[TBL] [Abstract][Full Text] [Related]
3. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
6. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
7. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods.
Yoroidaka T; Narita K; Takamatsu H; Fujisawa M; Nakao S; Matsue K
Sci Rep; 2021 May; 11(1):11218. PubMed ID: 34045494
[TBL] [Abstract][Full Text] [Related]
8. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.
Takamatsu H; Yoroidaka T; Fujisawa M; Kobori K; Hanawa M; Yamashita T; Murata R; Ueda M; Nakao S; Matsue K
Int J Hematol; 2019 Apr; 109(4):377-381. PubMed ID: 30778767
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
Oldaker TA; Wallace PK; Barnett D
Cytometry B Clin Cytom; 2016 Jan; 90(1):40-6. PubMed ID: 26201282
[TBL] [Abstract][Full Text] [Related]
10. Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma.
Royston DJ; Gao Q; Nguyen N; Maslak P; Dogan A; Roshal M
Am J Clin Pathol; 2016 Jul; 146(1):41-9. PubMed ID: 27402608
[TBL] [Abstract][Full Text] [Related]
11. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
12. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
[TBL] [Abstract][Full Text] [Related]
13. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.
Keeney M; Halley JG; Rhoads DD; Ansari MQ; Kussick SJ; Karlon WJ; Mehta KU; Dorfman DM; Linden MA
Arch Pathol Lab Med; 2015 Oct; 139(10):1276-80. PubMed ID: 25695342
[TBL] [Abstract][Full Text] [Related]
14. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
Rawstron AC; de Tute RM; Haughton J; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
[TBL] [Abstract][Full Text] [Related]
15. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
[TBL] [Abstract][Full Text] [Related]
16. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
17. Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.
Carulli G; Tarasco A; Sammuri P; Ottaviano V; Domenichini C; Ciancia EM; Petrini M
Clin Ter; 2019; 170(5):e352-e356. PubMed ID: 31612192
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
19. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
Al-Mawali A; Gillis D; Lewis I
Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
